Acurx Pharmaceuticals Launches New Clinical Trial for Recurrent Clostridioides difficile infection

Acurx Pharmaceuticals is preparing to launch a new clinical trial evaluating its lead antibiotic candidate Ibezapolstat for patients with multiply recurrent Clostridioides difficile infection (rCDI).

The study aims to determine whether ibezapolstat can both treat the infection and prevent recurrence, potentially replacing the current two-step treatment approach with a single therapy.

Trial start-up activities will begin later this month, with the first patient expected to enroll in the fourth quarter of 2026.

A New Approach to Prevent Recurrence

The upcoming open-label pilot trial will enroll up to 20 patients whose infection has recurred at least twice within the past 12 months following standard antibiotic therapy.

Researchers will evaluate how ibezapolstat performs in patients who have experienced three or more CDI episodes in one year.

Results from this pilot study will help shape the design of a future Phase 3 registration trial focused on recurrent CDI.

Encouraging Phase 2 Results

Previous Phase 2 data suggest ibezapolstat may deliver strong clinical outcomes.

Key findings from the trial include:

• 96% clinical cure rate (25 of 26 patients)
• 100% sustained cure at one month among patients who achieved initial clinical cure
• No recurrence observed in the five patients monitored for three months after treatment

In comparison, historical data for standard treatments such as Vancomycin show recurrence rates ranging from 20% to 40%.

The therapy was also well tolerated, with no serious adverse events attributed to the drug.

Protecting the Gut Microbiome

A key differentiator of ibezapolstat is its Gram-positive selective spectrum mechanism.

Unlike broad-spectrum antibiotics that disrupt the gut microbiome, ibezapolstat targets specific bacteria while preserving beneficial microbial species.

Recent laboratory data from Kevin Garey at the University of Houston suggest that beneficial gut bacteria remain present in patients even after multiple prior CDI treatments.

This creates an opportunity for healthy microbes to repopulate the gut after ibezapolstat therapy, potentially reducing the risk of recurrence.

Regulatory Pathway and Development Plans

Following the pilot trial, the company plans to initiate a Phase 3 clinical program for recurrent CDI.

If successful, Acurx intends to pursue approval through the FDA Limited Population Pathway for Antibacterial and Antifungal Drugs.

The drug has already received key regulatory designations:

• Qualified Infectious Disease Product (QIDP) status from the U.S. Food and Drug Administration
• Fast Track designation from the FDA
• SME designation from the European Medicines Agency

These designations support accelerated development of treatments addressing urgent public health threats.

A Major Public Health Challenge

According to estimates cited by the company, Clostridioides difficile infection affects around 500,000 people annually in the United States, causing roughly 30,000 deaths each year.

Recurrent infections are particularly costly, contributing to a $5 billion annual healthcare burden, with approximately $2.8 billion linked to recurrent CDI.

Potential Paradigm Shift in CDI Treatment

Robert J. DeLuccia, Executive Chairman of Acurx Pharmaceuticals, believes the therapy could transform treatment strategies.

He noted that ibezapolstat has shown potential to both cure CDI and prevent recurrence, which could significantly simplify disease management.

If future trials confirm these findings, ibezapolstat could become the first therapy to address both treatment and prevention of recurrent CDI with a single agent.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!